---
title: "SpyGlass Pharma: Buy Rating Reiterated as Late-Stage Glaucoma Pipeline Advances; $37 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295276993.md"
description: "H.C. Wainwright analyst Yi Chen reiterated a Buy rating on SpyGlass Pharma with a $37 price target, citing advancing late-stage glaucoma pipelines and strong finances. Phase 3 BIM-IOL trials are on track for 2027 enrollment completion, with key data expected in late 2026. The upcoming first-in-human BIM-DRS trial offers potential for lifetime treatment. Supported by sufficient cash reserves through 2028 and DCF valuation, the rating stands despite inherent clinical and regulatory risks."
datetime: "2026-08-07T20:45:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295276993.md)
  - [en](https://longbridge.com/en/news/295276993.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295276993.md)
generator: "portal-rs"
---

# SpyGlass Pharma: Buy Rating Reiterated as Late-Stage Glaucoma Pipeline Advances; $37 Price Target Maintained

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on SpyGlass Pharma today and set a price target of $37.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Yi Chen has given his Buy rating due to a combination of factors, primarily centered on SpyGlass Pharma’s advancing clinical programs and solid financial position. The company’s Phase 3 BIM-IOL trials are progressing as planned, with enrollment expected to complete in 2027 and meaningful four-year follow-up data from the first-in-human study anticipated in late 2026, supporting confidence in long-term efficacy and safety.

Yi Chen’s optimism is further underpinned by the upcoming first-in-human BIM-DRS trial, which could broaden SpyGlass’s reach across glaucoma and ocular hypertension patients while enabling repeated treatment over a lifetime. Together with a cash balance that appears sufficient to fund operations through at least 2028, and a DCF-based valuation that supports a $37 price target, these elements collectively justify maintaining a Buy rating despite typical clinical, regulatory, commercial, and dilution risks.

### Related Stocks

- [SGP.US](https://longbridge.com/en/quote/SGP.US.md)

## Related News & Research

- [Spyglass Pharma posts corporate deck on long-acting intraocular drug delivery for glaucoma, ocular hypertension patients](https://longbridge.com/en/news/295701214.md)
- [Innocan Pharma reports Q2 results](https://longbridge.com/en/news/297557245.md)
- [Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility](https://longbridge.com/en/news/297493563.md)
- [Alliance Global Partners Sticks to Their Buy Rating for Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/297544479.md)
- [Wildcat Resources Ltd. (WC8) Receives a Buy from Shaw and Partners](https://longbridge.com/en/news/297627932.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**